AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25942417 — intervention group
Group type: COMPARATOR
Intervention: Non-gadolinium-based contrast agent (non-GBCA)
Number of subjects: 10
Study 23287637 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecure-avoidant infants
Number of subjects: 84
Study 23287637 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure infants
Number of subjects: 84
Study 23287637 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecure-ambivalent infants
Number of subjects: 84
Study 23287637 — intervention group
Group type: COMPARATOR
Intervention: Attachment groups at 5 months
Number of subjects: 84
Study 21664710 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-45Gy in 20-23 fractions for indolent NHL
Number of subjects: 1001
Study 21664710 — intervention group
Group type: COMPARATOR
Intervention: 24Gy in 12 fractions for indolent NHL
Number of subjects: 1001
Study 21664710 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-45Gy in 20-23 fractions for aggressive NHL
Number of subjects: 1001
Study 21664710 — intervention group
Group type: COMPARATOR
Intervention: 30Gy in 15 fractions for aggressive NHL
Number of subjects: 1001
Study 21664710 — intervention group
Group type: COMPARATOR
Intervention: Low-dose arms (24Gy for indolent NHL and 30Gy for aggressive NHL)
Number of subjects: 1001
Study 21664710 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses (40-45Gy)
Number of subjects: 1001
Study 18047499 — intervention group
Group type: EXPERIMENTAL
Intervention: IV DEX (15 mg)
Number of subjects: 126
Study 18047499 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 126
Study 16183189 — intervention group
Group type: COMPARATOR
Intervention: NMC group
Number of subjects: 55
Study 16183189 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 55
Study 16183189 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular prorenin concentrations in PCOS
Number of subjects: 55
Study 12680834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tubes with adenoidectomy
Number of subjects: 0
Study 12680834 — intervention group
Group type: COMPARATOR
Intervention: Ventilation tubes without adenoidectomy
Number of subjects: 0
Study 12680834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ears with functioning ventilation tubes
Number of subjects: 0
Study 12680834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ears without OME after tube extrusion
Number of subjects: 0
Study 12680834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube blockage
Number of subjects: 0
Study 12680834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tubes
Number of subjects: 0
Study 10875182 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-based technique for measuring accuracy and distortion in judgments of linear dimensions
Number of subjects: 0
Study 10875182 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-based technique
Number of subjects: 0
Study 9170037 — intervention group
Group type: EXPERIMENTAL
Intervention: sprodiamide injection at 0.1 mmol/kg
Number of subjects: 35
Study 9170037 — intervention group
Group type: EXPERIMENTAL
Intervention: sprodiamide injection at 0.2 mmol/kg
Number of subjects: 35
Study 9170037 — intervention group
Group type: EXPERIMENTAL
Intervention: sprodiamide injection at 0.3 mmol/kg
Number of subjects: 35
Study 9170037 — intervention group
Group type: EXPERIMENTAL
Intervention: sprodiamide injection at 0.1 mmol/kg at 2 ml/second
Number of subjects: 35
Study 9170037 — intervention group
Group type: EXPERIMENTAL
Intervention: sprodiamide injection at 0.2 mmol/kg at 2 ml/second
Number of subjects: 35
Study 9170037 — intervention group
Group type: EXPERIMENTAL
Intervention: sprodiamide injection at 0.3 mmol/kg at 2 ml/second
Number of subjects: 35
Study 9170037 — intervention group
Group type: EXPERIMENTAL
Intervention: sprodiamide injection at 0.1 mmol/kg at 5 ml/second
Number of subjects: 35
Study 9170037 — intervention group
Group type: EXPERIMENTAL
Intervention: sprodiamide injection at 0.2 mmol/kg at 5 ml/second
Number of subjects: 35
Study 9170037 — intervention group
Group type: EXPERIMENTAL
Intervention: sprodiamide injection at 0.3 mmol/kg at 5 ml/second
Number of subjects: 35
Study 9170037 — intervention group
Group type: EXPERIMENTAL
Intervention: sprodiamide injection
Number of subjects: 35
Study 1492860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (DHEC) 6 mg tablet
Number of subjects: 6
Study 1492860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (DHEC) 3 ml drops (2 mg/ml)
Number of subjects: 6
Study 1492860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (DHEC) single-dose bottle (6 mg)
Number of subjects: 6
Study 3514474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 116
Study 3514474 — intervention group
Group type: COMPARATOR
Intervention: Pipemidic acid
Number of subjects: 116
Study 3514474 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole forte
Number of subjects: 116
Study 31646578 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX9 siRNA
Number of subjects: 0
Study 31646578 — intervention group
Group type: COMPARATOR
Intervention: High glucose group
Number of subjects: 0
Study 31646578 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30095593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun Safe Workplaces (SSW) program
Number of subjects: 1724
Study 27931302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microgram daily dose
Number of subjects: 80
Study 27931302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microgram daily combined with LABA (formoterol)
Number of subjects: 80
Study 27931302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microgram daily combined with LTRA (montelukast)
Number of subjects: 80
Study 27931302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microgram daily dose
Number of subjects: 80
Study 23183711 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (dopamine‐receptor agonist)
Number of subjects: 22
Study 23183711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (dopamine‐receptor antagonist)
Number of subjects: 22
Study 23183711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 22
Study 23183711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 23183711 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bromocriptine and sulpiride
Number of subjects: 22
Study 22244646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA) in phosphate-buffered saline (PBS) (pH = 7.4) for 4 days
Number of subjects: 80
Study 22244646 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioaggregate (BA) in phosphate-buffered saline (PBS) (pH = 7.4) for 4 days
Number of subjects: 80
Study 22244646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA) in acetic acid (pH = 5.4) for 4 days
Number of subjects: 80
Study 22244646 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioaggregate (BA) in acetic acid (pH = 5.4) for 4 days
Number of subjects: 80
Study 22244646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA) in phosphate-buffered saline (PBS) for 34 days
Number of subjects: 80
Study 22244646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA) in PBS for 34 days
Number of subjects: 80
Study 22244646 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioaggregate (BA) in PBS for 34 days
Number of subjects: 80
Study 19189319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplant (HSCT) couples
Number of subjects: 121
Study 16960155 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multivitamin supplementation (5 mg folic acid, 50 mg pyridoxine, and 0.4 mg cyanocobalamin)
Number of subjects: 701
Study 16960155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 15747154 — intervention group
Group type: EXPERIMENTAL
Intervention: [(18)F]FDG-PET
Number of subjects: 26
Study 12456421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 3.0 or 3.5 mg/kg with lidocaine spray
Number of subjects: 90
Study 12456421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (various doses)
Number of subjects: 90
Study 12456421 — intervention group
Group type: COMPARATOR
Intervention: Propofol (various doses)
Number of subjects: 90
Study 10479851 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (60 micrograms in 250 cc of physiological infusion for six consecutive days)
Number of subjects: 12
Study 10479851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 cc of physiological infusion administered in the same manner)
Number of subjects: 12
Study 8686826 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium with halothane
Number of subjects: 30
Study 8686826 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium with isoflurane
Number of subjects: 30
Study 8686826 — intervention group
Group type: COMPARATOR
Intervention: Doxacurium with alfentanil
Number of subjects: 30
Study 1878531 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (200 mg)
Number of subjects: 10
Study 6958487 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms daily, administered twice a day)
Number of subjects: 93
Study 6958487 — intervention group
Group type: EXPERIMENTAL
Intervention: Becotide Nasal (400 micrograms daily, administered four times a day)
Number of subjects: 93
Study 31027889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound-guided dry-weight reduction
Number of subjects: 71
Study 31027889 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment
Number of subjects: 71
Study 29977265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (group A, n=40)
Number of subjects: 60
Study 29977265 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (group B, n=40)
Number of subjects: 60
Study 26868369 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled mometasone
Number of subjects: 45
Study 26868369 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive randomization
Number of subjects: 45
Study 26868369 — intervention group
Group type: COMPARATOR
Intervention: Simple randomization
Number of subjects: 45
Study 26868369 — intervention group
Group type: COMPARATOR
Intervention: Block randomization
Number of subjects: 45
Study 25132278 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cationic airway lining modulator (iCALM) - 1.29% calcium chloride in 0.9% isotonic saline
Number of subjects: 6
Study 25132278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 22378177 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal cerebellar transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study 22378177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal cerebellar transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study 22378177 — intervention group
Group type: COMPARATOR
Intervention: Cerebellar tDCS (both anodal and cathodal)
Number of subjects: 0
Study 22378177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS
Number of subjects: 0
Study 19942107 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga sessions lasting 60 min daily
Number of subjects: 88
Study 19942107 — intervention group
Group type: COMPARATOR
Intervention: Brief supportive therapy once in 10 days
Number of subjects: 88
Study 17439537 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers' reports of immunisations
Number of subjects: 160
Study 17439537 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers' reports of infant doctors' visits
Number of subjects: 160
Study 17439537 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers' reports of sick-baby visits
Number of subjects: 160
Study 17439537 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between mothers' reports and medical records
Number of subjects: 160
Study 17439537 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancies in reporting
Number of subjects: 160
Study 17439537 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency room visits
Number of subjects: 160
Study 15782505 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.02 mg/kg) and atropine (0.01 mg/kg) infusion in group C and group D after neuromuscular recovery (T1/T(C)) reached 10%.
Number of subjects: 40
Study 15782505 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (MgSO4) 30 mg/kg in saline intravenously within 5 min in group A and group C.
Number of subjects: 40
Study 15782505 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion in group B and group D.
Number of subjects: 40
Study 15782505 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine and atropine infusion in group C and group D.
Number of subjects: 40
Study 11939813 — intervention group
Group type: EXPERIMENTAL
Intervention: Exotoxin reconstituted with preservative-containing saline
Number of subjects: 35
Study 11939813 — intervention group
Group type: COMPARATOR
Intervention: Exotoxin reconstituted with preservative-free saline
Number of subjects: 35
Study 9588456 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected sib-pair linkage analysis for nephropathy
Number of subjects: 201
Study 9588456 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected sib-pair linkage analysis for retinopathy
Number of subjects: 201
Study 8583661 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetated Ringer (AR) solution
Number of subjects: 20
Study 8583661 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer (LR) solution
Number of subjects: 20
Study 1976928 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of Ty21a vaccine
Number of subjects: 81621
Study 1976928 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated capsules of Ty21a vaccine
Number of subjects: 81621
Study 1976928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81621
Study 90214 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (average 97 mg/day, range 30-130 mg)
Number of subjects: 100
Study 90214 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with gradual reduction of methadone at 1 mg/day)
Number of subjects: 100
Study 90214 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 100
Study 90214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31774956 — intervention group
Group type: EXPERIMENTAL
Intervention: Satralizumab (120 mg, subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter)
Number of subjects: 83
Study 31774956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter)
Number of subjects: 83
Study 31774956 — intervention group
Group type: EXPERIMENTAL
Intervention: Satralizumab (among 55 AQP4-IgG-seropositive patients)
Number of subjects: 83
Study 31774956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (among 55 AQP4-IgG-seropositive patients)
Number of subjects: 83
Study 31774956 — intervention group
Group type: EXPERIMENTAL
Intervention: Satralizumab (among 28 AQP4-IgG-seronegative patients)
Number of subjects: 83
Study 31774956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (among 28 AQP4-IgG-seronegative patients)
Number of subjects: 83
Study 31774956 — intervention group
Group type: EXPERIMENTAL
Intervention: Satralizumab
Number of subjects: 83
Study 31774956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 27279547 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoBT (autogenous tooth graft material)
Number of subjects: 24
Study 27279547 — intervention group
Group type: COMPARATOR
Intervention: Bio-Oss® (anorganic bovine bone)
Number of subjects: 24
Study 26349753 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 20
Study 26349753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23954036 — intervention group
Group type: EXPERIMENTAL
Intervention: Beat the Blues (BTB) depression intervention
Number of subjects: 208
Study 23954036 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 208
Study 22888979 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visiting program targeting child mental health
Number of subjects: 440
Study 18925434 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-node-based management (SNBM)
Number of subjects: 643
Study 18925434 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymph-node dissection (ALND)
Number of subjects: 643
Study 18925434 — intervention group
Group type: EXPERIMENTAL
Intervention: SSSS arm symptoms scale
Number of subjects: 643
Study 18925434 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire SSSS
Number of subjects: 643
Study 18925434 — intervention group
Group type: EXPERIMENTAL
Intervention: Single items rated by patients
Number of subjects: 643
Study 17202432 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (2 mg/24 h titrated to 6 mg/24 h)
Number of subjects: 277
Study 17202432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 15265001 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate diet (<10% energy via carbohydrate)
Number of subjects: 15
Study 15265001 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (<30% energy via fat)
Number of subjects: 15
Study 15265001 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate diet
Number of subjects: 15
Study 15265001 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 15
Study 15265001 — intervention group
Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 15
Study 15265001 — intervention group
Group type: COMPARATOR
Intervention: Neither diet
Number of subjects: 15
Study 11407200 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective controlled clinical trials
Number of subjects: 0
Study 11407200 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel and crossover studies
Number of subjects: 0
Study 11407200 — intervention group
Group type: EXPERIMENTAL
Intervention: Open pilot studies
Number of subjects: 0
Study 11407200 — intervention group
Group type: COMPARATOR
Intervention: Controlled clinical trials
Number of subjects: 0
Study 8980757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 121
Study 8980757 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 121
Study 7685147 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 at 0.05 mg/kg/day
Number of subjects: 53
Study 7685147 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 at 0.10 mg/kg/day
Number of subjects: 53
Study 7685147 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 at 0.15 mg/kg/day
Number of subjects: 53
Study 7685147 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 at 0.20 mg/kg/day
Number of subjects: 53
Study 7685147 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 with dosage adjustment
Number of subjects: 53
Study 7685147 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 therapy
Number of subjects: 53
Study 3553591 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms lipo-PGE1
Number of subjects: 135
Study 3553591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 28378150 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual feedback device (TrueCPR™, Physio-Control)
Number of subjects: 48
Study 28378150 — intervention group
Group type: COMPARATOR
Intervention: No feedback information
Number of subjects: 48
Study 27387203 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk Well intervention (12-week physical activity consultation-led walking intervention)
Number of subjects: 102
Study 27387203 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 102
Study 24610884 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SBP target group (<130mm Hg)
Number of subjects: 0
Study 24610884 — intervention group
Group type: COMPARATOR
Intervention: Higher SBP target group (130‐149mm Hg)
Number of subjects: 0
Study 23609390 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU of vitamin D (G300)
Number of subjects: 120
Study 23609390 — intervention group
Group type: EXPERIMENTAL
Intervention: 150,000 IU of vitamin D (G150)
Number of subjects: 120
Study 23609390 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NTG)
Number of subjects: 120
Study 20887513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse® (CPP‐ACP gel; GC‐Corp, Tokyo, Japan)
Number of subjects: 21
Study 20887513 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridin N5® (Fluoride gel; Voco‐GmbH, Cuxhaven, Germany)
Number of subjects: 21
Study 20887513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study 18712607 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive telephonic intervention (6 sessions of problem-focused counseling)
Number of subjects: 23
Study 18712607 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 participants)
Number of subjects: 23
Study 15456009 — intervention group
Group type: EXPERIMENTAL
Intervention: Minolta VIVID 700 portable non‐contact 3D laser scanner
Number of subjects: 15
Study 15456009 — intervention group
Group type: COMPARATOR
Intervention: Structured light pattern techniques (lines and dots)
Number of subjects: 15
Study 10321135 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7642432 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiotherapy (50 + 10 Gy)
Number of subjects: 101
Study 7642432 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (no radiotherapy)
Number of subjects: 101
Study 2750356 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms sulprostone gel
Number of subjects: 40
Study 2750356 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms sulprostone gel
Number of subjects: 40
Study 2750356 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms sulprostone gel
Number of subjects: 40
Study 2750356 — intervention group
Group type: COMPARATOR
Intervention: gel vehicle tylose
Number of subjects: 40
Study 792490 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 27
Study 792490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27